A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

NCT07464327 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: HS-20093
DRUG: Docetaxel

Sponsor

Hansoh BioMedical R&D Company